DNA vaccination against bcr-abl-positive cells in mice

被引:12
|
作者
Lucansky, Vincent [1 ]
Sobotkova, Eva [1 ]
Tachezy, Ruth [1 ]
Duskova, Martina [1 ]
Vonka, Vladimir [1 ]
机构
[1] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague 2, Czech Republic
关键词
CML; bcr-abl-transformed mouse cells; DNA vaccines; CHRONIC MYELOGENOUS LEUKEMIA; LOADED DENDRITIC CELLS; IMATINIB MESYLATE; FUSION PEPTIDES; IMMUNOTHERAPY; ONCOGENE; IMMUNOGENICITY; TRANSFORMATION; MECHANISMS; DISEASE;
D O I
10.3892/ijo_00000408
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A series of DNA vaccines based on the bcr-abl fusion gene were developed and tested in mice. Two mouse (BALB/c) bcr-abl-transformed cell lines, B210 and 12131, which both expressed p210(bcr-abl) and were oncogenic for syngeneic animals but differed in some other respects, were used as a model system. In the first series of experiments, plasmids carrying either the complete bcr-abl fusion gene or a fragment thereof coding for a 25-amino acid-long junction zone (bcr-abl25aa) linked with genes coding for a variety of immunostimulatory factors were used as the DNA vaccines. A plasmid carrying the complete bcr-abl gene was capable of inducing protection against challenge with either B210 or 12B1 cells. However, the DNA vaccines based on the gene fragment coding for p25aa(bcr-abl) did not induce significant protection. To localize the immunizing epitopes on the p210(bcr-abl) protein, the whole fusion gene was split into nine overlapping fragments and these, individually or in various combinations, were used for immunization. Although none of the vaccines based on any single fragment provided potent protection, some combinations of these fragment-based vaccines were capable of eliciting protection comparable to that seen after immunization with the whole-gene vaccine. Surprisingly, a mixture of six fragment-vaccines was more immunogenic than the complete set of fragment DNA vaccines. To analyze this phenomenon, the three fragments missing from the hexavaccine were either individually or in various combinations mixed with the hexavaccine. The results obtained suggested that the product of the fragment coding for 197 amino acids forming the N-terminal of the BCR protein was involved in the decreased immunogenicity. However, further experiments are needed to clarify the point. Additional experiments revealed that all the important epitopes were located in the ABL portion of the p210(bcr-abl) protein. The livers, spleens and bone marrows of the successfully immunized animals were tested for the presence of bcr-abl-positive cells by RT-PCR. The results were negative, this suggesting that these animals were free of any residual disease.
引用
收藏
页码:941 / 951
页数:11
相关论文
共 50 条
  • [21] Imatinib restores expression of CD62L in BCR-ABL-positive cells
    Fruehauf, S
    Topaly, J
    Schad, M
    Paschka, P
    Gschaidmeier, H
    Zeller, WJ
    Hochhaus, A
    Ho, AD
    JOURNAL OF LEUKOCYTE BIOLOGY, 2003, 73 (05) : 600 - 603
  • [22] BCR-ABL-POSITIVE AND BCR-ABL-NEGATIVE CLONOGENIC CELLS IN CML PATIENTS UNDERGOING LONG-TERM INTERFERON TREATMENT
    WANDL, UB
    BUTZLER, R
    NIEDERLE, N
    KLOKE, O
    MENGELKOCH, B
    BECHER, R
    SEEBER, S
    OPALKA, B
    LEUKEMIA, 1994, 8 (05) : 776 - 779
  • [23] BCL-2 antisense oligonuicleotide genasense is active against imatinib-resistant BCR-ABL-positive cells
    Tauchi, T
    Sumi, M
    Nakajima, A
    Sashida, G
    Shimamoto, T
    Ohyashiki, K
    CLINICAL CANCER RESEARCH, 2003, 9 (11) : 4267 - 4273
  • [24] Discovery of a novel Abl tyrosine kinase inhibitor that selectively induces apoptosis of Bcr-Abl-positive leukemic cells
    Dorsey, JF
    Jove, R
    Kraker, A
    Wu, J
    Zuckerman, KS
    EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) : 49 - 49
  • [25] Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL-Positive Cells
    Kominsky, Douglas J.
    Klawitter, Jelena
    Brown, Jaimi L.
    Boros, Laszlo G.
    Melo, Junia V.
    Eckhardt, S. Gail
    Serkova, Natalie J.
    CLINICAL CANCER RESEARCH, 2009, 15 (10) : 3442 - 3450
  • [26] Specific inhibition of hTERT by shRNA sensitizes for imatinib mesylate in BCR-ABL-positive cells.
    Sashida, G
    Tauchi, T
    Sumi, M
    Nakajima, A
    Ohyashiki, JH
    Ohyashiki, K
    BLOOD, 2004, 104 (11) : 169B - 169B
  • [27] Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
    Lichtman, Marshall A.
    ONCOLOGIST, 2008, 13 (06): : 645 - 654
  • [28] IMPENDING CARDIAC TAMPONADE AS THE INITIAL MANIFESTATION OF BCR-ABL-POSITIVE CML
    Gaballa, Salem
    Hlaing, Kyaw
    Moursy, Safa
    Ahmed, Ameenjamal
    Patel, Brijesh
    Rallis, Austin
    Dexter, David
    CHEST, 2020, 158 (04) : 1021A - 1022A
  • [29] Purging of peripheral blood stem cells yields BCR-ABL-negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemia
    Martin, H
    Atta, J
    Zumpe, P
    Eder, M
    Elsner, S
    Rode, C
    Wassmann, B
    Bruecher, J
    Hoelzer, D
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (14) : 1612 - 1618
  • [30] The anti-apoptotic role of the unfolded protein response in Bcr-Abl-positive leukemia cells
    Tanimura, Atsuko
    Yujiri, Toshiaki
    Tanaka, Yoshinori
    Hatanaka, Masayuki
    Mitani, Noriyuki
    Nakamura, Yukinori
    Mori, Kazutoshi
    Tanizawa, Yukio
    LEUKEMIA RESEARCH, 2009, 33 (07) : 924 - 928